Abiomed Executive Compensation (FY22)
ABMD · Executive and director compensation, fiscal 2022 only
The Abiomed brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): August 12, 2022
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
245 figures on this page: 221 cited to the filing that reported them, 24 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Abiomed's chief executive and what were they paid?
Total compensation for Michael Minogue, Chairman of the Board, President, Chief Executive Officer, came to $12,665,992 in fiscal 2022.
What was Abiomed's say-on-pay result?
For fiscal 2022, the say-on-pay proposal drew 36.1% support at the meeting held August 10, 2022.
Which companies are in Abiomed's peer group?
The disclosed peer group includes Atricure, Inc., Avanos Medical, Inc., CONMED Corporation, DexCom, Inc. and Edwards Lifesciences Corporation, among others.
What is Abiomed's chief executive pay ratio?
For fiscal 2022, the company reported a chief executive pay ratio of 96:1, against median employee compensation of $131,893.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Minogue Chairman of the Board, President, Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Todd Trapp Executive Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrew Greenfield Executive Vice President and Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Marc Began Executive Vice President, General Counsel | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
David Weber Former Senior Vice President and Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew J. Greenfield | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew J. Greenfield | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Andrew J. Greenfield | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| David M. Weber | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| David M. Weber | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Marc A. Began | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Marc A. Began | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Marc A. Began | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Michael R. Minogue | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael R. Minogue | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael R. Minogue | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Todd A. Trapp | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Todd A. Trapp | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Todd A. Trapp | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| David Weber | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| PSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — | |
| Andrew Greenfield | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Todd Trapp | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Minogue | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | = | — | — | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | = | — | — | |
| Marc Began | RSU | ◇ | = | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Paula A. Johnson | ◇ | ◇ | — | — | — | — | ◇ |
Dorothy E. Puhy Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Paul G. Thomas | ◇ | ◇ | — | — | — | — | ◇ |
Martin P. Sutter | ◇ | ◇ | — | — | — | — | ◇ |
Jeannine M. Rivet | ◇ | ◇ | — | — | — | — | ◇ |
Christopher D. Van Gorder | ◇ | ◇ | — | — | — | — | ◇ |
Myron L. Rolle | ◇ | ◇ | — | — | — | — | ◇ |
Eric A. Rose | ◇ | ◇ | — | — | — | — | ◇ |
W. Gerald Austen | ◇ | ◇ | — | — | — | — | ◇ |
Michael R. Minogue served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Atricure, Inc. ATRC
- Avanos Medical, Inc. AVNS
- CONMED Corporation CNMD
- DexCom, Inc. DXCM
- Edwards Lifesciences Corporation EW
- Globus Medical, Inc. GMED
- Haemonetics Corporation HAE
- ICU Medical, Inc. ICUI
- Inogen, Inc. INGN
- Integra LifeSciences Holdings Corporation IART
- LivaNova PLC LIVN
- Masimo Corporation MASI
- Merit Medical Systems, Inc. MMSI
- Natus Medical Incorporated symbol not shown
- Nevro Corp. NVRO
- NuVasive, Inc. NUVA
- Penumbra, Inc. PEN
- ResMed Inc. RMD
- Teleflex Incorporated TFX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2022 | August 10, 2022 | = | ◇ | ◇ | ◇ |
| 2021 | August 11, 2021 | = | ◇ | ◇ | ◇ |
| 2020 | August 12, 2020 | = | ◇ | ◇ | ◇ |
| 2019 | August 7, 2019 | = | ◇ | ◇ | ◇ |
| 2018 | August 8, 2018 | = | ◇ | ◇ | ◇ |
| 2017 | August 9, 2017 | = | ◇ | ◇ | ◇ |
| 2016 | August 10, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Abiomed disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Abiomed sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Abiomed recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
245 figures on this page: 221 cited to the filing that reported them, 24 calculated from figures it prints.
221 cited to the filing
24 calculated from the filing
Documents cited
- 0000950170-22-017121Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-183958Compensation of Directors · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
- 0001564590-21-044296Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-220379Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-19-031282Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-18-246092Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-258646Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-16-679330Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Abiomed executive compensation, FY2022.” https://intel.velarion.ai/comp/ABMD (accessed 2026).
Short form: data: Velarion
The Abiomed brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Abiomed and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Abiomed discloses
The companies named in ABMD's own disclosed peer group.
Atricure, Inc.Avanos Medical, Inc.CONMED CorporationDexCom, Inc.Edwards Lifesciences CorporationGlobus Medical, Inc.Haemonetics CorporationICU Medical, Inc.Inogen, Inc.Integra LifeSciences Holdings CorporationLivaNova PLCMasimo CorporationMerit Medical Systems, Inc.Nevro Corp.NuVasive, Inc.Penumbra, Inc.ResMed Inc.Teleflex Incorporated
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}